Author: admin
Andrew Badrot, C2 PHARMA CEO, is interviewed by MJH Life Sciences during CPhI 2022 in Frankfurt and discusses the future of the company and the CMO industry in general
Sarah Breen, Senior Quality Manager at C2 PHARMA, shares her thoughts on supplier oversight with Susan Haigney from Pharmaceutical Technology
C2 PHARMA Expands Ophthalmic API Portfolio with Tropicamide Launch & Multiple Regulatory Filings
C2 PHARMA at CPhI 2022 in Frankfurt
What Goes Wrong When API Quality is Compromised?
C2 PHARMA Completes Multiple Local Regulatory Filings and Expands Portfolio
C2 PHARMA at CPhI 2021 in Milan
Pharmaceutical reshoring: a healthy requirement, a strategic necessity – a Manufacturing Chemist Featured Story
C2 PHARMA Completes Multiple Regulatory Filings, Expands Portfolio
Andrew Badrot, C2 PHARMA CEO, speaks on working to mitigate risks for future crises like the COVID-19 pandemic
Interview with Andrew Badrot, C2 PHARMA CEO, a “Lëtzebuerger Merkur” Featured Story
C2 PHARMA Finalist in Excellence in Pharma: Sustainability, the CPhI Pharma Awards 2020
The Impact of Covid-19 on the Pharmaceutical Industry
Connecting industry across the globe, a Chemicals Knowledge featured story
Andrew Badrot, CEO of C2 PHARMA, speaks on how the pharma industry has responded to the COVID-19 pandemic, a Pharma’s Almanac Q2 issue
Lessons from a modern-day pandemic: redesigning the pharmaceutical supply chain, a Manufacturing Chemist featured story
COVID-19/Coronavirus is reshaping the pharmaceutical supply chain
C2 PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19/Coronavirus Combination Treatment
Andrew Badrot, CEO of C2 PHARMA, weighs in on the future trends of mergers and acquisitions in the life sciences industry
C2 PHARMA highlights importance of API quality
Fairness in the pharma supply chain key to success in today’s business climate
Andrew Badrot, CEO of C2 PHARMA, speaks on developing technologies that will have the greatest impact on the biopharma industry in 2020 and beyond, a Pharma’s Almanac Q4 issue
C2 PHARMA continues to expand API portfolio
C2 PHARMA Continues to Expand API Portfolio with Digoxin Micronized Grade, Homatropine Hydrobromide and Multiple Products Under Tech Transfer and Development
C2 PHARMA leverages virtual manufacturing to build secure supply chains, a Chemicals Knowledge featured story
Why the industry is forming bonds with CBD
Building resilient supply chains for niche APIs How C² PHARMA overcame the Digoxin challenge
C2 PHARMA Acquires Digoxin API Portfolio from Nobilus Ent
FINANCIAL TIMES GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY CONFERENCE
Validation
C2 PHARMA leads
Acquisition
Willkommen zur deutschen Version von WordPress. Dies ist der erste Beitrag. Du kannst ihn bearbeiten oder löschen. Und dann starte mit dem Schreiben!